John Crowley, President and CEO of Cancer Research and Biostatistics will speak at OHSU on Monday, March 29 from 12 to 1 p.m. in University Hospital South, Room 8B60.
Dr. Crowley will speak about properly designing clinical trials that utilize targeted agents. The development of anticancer compounds targeted at specific features of the cancer cell has raised questions about appropriate clinical trial designs to move such agents forward. Dr. Crowley will share some thoughts about and experiences with:
- Finding a good dose in Phase I/II trials
- Phase II designs, randomized or not
- Early monitoring for futility in Phase II/III designs
- Phase III designs for targeted agents
This event is sponsored by OCTRI and the Oregon Translational Research and Drug Development Institute (OTRADI).